Subscribe or Manage Preferences

Cost per Response for Abatacept versus Adalimumab in Patients with Seropositive, Erosive Early RA

VBCR - December 2017, Vol 6, No 5 - ACR 2017 Conference Correspondent, Rheumatoid Arthritis

A post hoc analysis of the head-to-head, randomized Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Subjects with Background Methotrexate (AMPLE) trial demonstrated that subcutaneous (SC) abatacept treatment showed improved efficacy versus SC adalimumab in patients with seropositive, erosive early rheumatoid arthritis (RA).

A previously described decision tree was used to compare the cost per response and per patient in remission for abatacept and adalimumab in a cohort of 1000 patients from 4 countries—United States, Canada, Germany, and Spain—over a 2-year period. Patients with or without seropositive, erosive early RA from the post hoc analysis of the AMPLE trial, who were defined as disease duration ≤6 months, rheumatoid factor or anticitrullinated protein antibody seropositive, and with >1 radiographic erosion were included. Response assessment was based on American College of Rheumatology 20%/50%/70%/90% improvement criteria (ACR20/ACR50/ACR70/ACR90), and Health Assessment Questionnaire Disability Index (HAQ-DI). Direct medical costs of adverse events were based on local tariffs for disease-related groups, and drug costs were obtained from ex-manufacturer price, including mandatory reductions, payback, and transparent discounts for drugs.

For ACR20, ACR50, ACR70, ACR90, and HAQ-DI responses assessed in this analysis, the cost per response in patients with seropositive, erosive early RA favored SC abatacept compared with SC adalimumab across all countries. Moreover, in both subgroups with or without seropositive, erosive early RA, cost per ACR90 and HAQ-DI response consistently favored SC abatacept in all countries. In the United States, compared with adalimumab, the monthly cost per responding patient for abatacept in erosive early RA was −$918 for ACR20, −$1352 for ACR50, −$4175 for ACR70, −$124,174 for ACR90, and −$363 for HAQ-DI. In terms of cost per remission, for patients with seropositive, erosive early RA in all countries, the cost per Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) remission also favored SC abatacept. However, in the United States and Canada, the cost per Disease Activity Score 28 (DAS28) remission favored SC adalimumab. In the United States, the monthly cost per patient in remission in erosive early RA was +$622 for DAS28, −$8015 for CDAI, and −$8015 for SDAI. For patients without seropositive, erosive early RA, the results were less favorable for SC abatacept for most countries, except in Germany and Spain, where the cost of abatacept is lower than the cost of adalimumab.

These results support the cost-efficiency benefit of SC abatacept compared with SC adalimumab in patients with seropositive, erosive early RA.

Source: Foo J, Rodriguez Heredia JM, Polanco Sánchez C, et al. Cost per response for abatacept versus adalimumab in patients with seropositive, erosive, early rheumatoid arthritis in the US, Germany, Spain and Canada. Arthritis Rheumatol. 2017;69(suppl 10). Abstract 1465.

Related Items
Web-Based Smartphone Application Useful for Monitoring Changes in RA Disease Activity
Sophie Granger
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in Rheumatoid Arthritis
Upadacitinib Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Efficacy and Safety of Switching from Adalimumab to Sarilumab
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Cost per Effectively Treated Patient with Sarilumab for Active, Moderate-to-Severe RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Suboptimal EHR Reporting of Clinical Measures in Patients with RA Receiving a Biologic or Targeted Synthetic DMARD
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Tocilizumab Monotherapy as Effective as TNF Inhibitors plus MTX in Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Sarilumab plus DMARDs Lower HbA1c in Diabetic and Nondiabetic Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Both Tofacitinib and Baricitinib in Combination with MTX Are Efficacious in Patients with RA
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in ACR 2017 Conference Correspondent, Rheumatoid Arthritis
Last modified: January 15, 2018
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology